Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 271 | 2024 | 17542 | 8.610 |
Why?
|
Anti-HIV Agents | 110 | 2024 | 4567 | 6.320 |
Why?
|
Cost-Benefit Analysis | 148 | 2024 | 5537 | 4.290 |
Why?
|
Anti-Retroviral Agents | 34 | 2023 | 1787 | 3.100 |
Why?
|
AIDS-Related Opportunistic Infections | 41 | 2015 | 663 | 3.090 |
Why?
|
Antiretroviral Therapy, Highly Active | 42 | 2019 | 1902 | 2.920 |
Why?
|
CD4 Lymphocyte Count | 88 | 2021 | 2586 | 2.860 |
Why?
|
Life Expectancy | 50 | 2024 | 1248 | 2.400 |
Why?
|
Health Care Costs | 43 | 2022 | 3239 | 2.000 |
Why?
|
Mass Screening | 40 | 2021 | 5456 | 1.910 |
Why?
|
South Africa | 66 | 2024 | 1873 | 1.800 |
Why?
|
Computer Simulation | 46 | 2024 | 6260 | 1.570 |
Why?
|
Acquired Immunodeficiency Syndrome | 21 | 2022 | 2204 | 1.560 |
Why?
|
Quality-Adjusted Life Years | 37 | 2024 | 1741 | 1.490 |
Why?
|
Homosexuality, Male | 19 | 2024 | 1344 | 1.320 |
Why?
|
Communicable Disease Control | 6 | 2024 | 856 | 1.270 |
Why?
|
AIDS Serodiagnosis | 12 | 2016 | 220 | 1.150 |
Why?
|
Infectious Disease Transmission, Vertical | 14 | 2023 | 1354 | 1.120 |
Why?
|
Benzoxazines | 6 | 2024 | 320 | 1.090 |
Why?
|
Viral Load | 25 | 2024 | 3385 | 1.040 |
Why?
|
Tuberculosis | 16 | 2021 | 2011 | 0.980 |
Why?
|
Chemoprevention | 8 | 2016 | 327 | 0.940 |
Why?
|
Models, Economic | 15 | 2020 | 719 | 0.940 |
Why?
|
HIV | 20 | 2023 | 1591 | 0.930 |
Why?
|
Heterocyclic Compounds, 3-Ring | 4 | 2024 | 296 | 0.920 |
Why?
|
HIV-1 | 29 | 2023 | 6951 | 0.910 |
Why?
|
Medication Adherence | 7 | 2020 | 2191 | 0.880 |
Why?
|
Ambulatory Care Facilities | 9 | 2020 | 939 | 0.870 |
Why?
|
Drug Resistance, Viral | 12 | 2020 | 868 | 0.850 |
Why?
|
Drug Monitoring | 6 | 2018 | 963 | 0.850 |
Why?
|
Models, Theoretical | 22 | 2024 | 3561 | 0.820 |
Why?
|
Adult | 185 | 2024 | 223317 | 0.810 |
Why?
|
RNA, Viral | 23 | 2018 | 2867 | 0.780 |
Why?
|
HIV Integrase Inhibitors | 3 | 2020 | 165 | 0.770 |
Why?
|
Disease Transmission, Infectious | 5 | 2017 | 560 | 0.750 |
Why?
|
Humans | 332 | 2024 | 767040 | 0.750 |
Why?
|
Male | 196 | 2024 | 364203 | 0.740 |
Why?
|
Drug Costs | 16 | 2020 | 1196 | 0.740 |
Why?
|
Cote d'Ivoire | 16 | 2023 | 65 | 0.730 |
Why?
|
Models, Biological | 23 | 2021 | 9464 | 0.710 |
Why?
|
Developing Countries | 10 | 2022 | 2911 | 0.690 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2020 | 52 | 0.680 |
Why?
|
Female | 201 | 2024 | 396660 | 0.670 |
Why?
|
Patient Compliance | 10 | 2017 | 2697 | 0.670 |
Why?
|
India | 11 | 2022 | 2334 | 0.650 |
Why?
|
Nevirapine | 5 | 2015 | 273 | 0.640 |
Why?
|
Mobile Health Units | 3 | 2015 | 93 | 0.630 |
Why?
|
Policy | 1 | 2022 | 513 | 0.610 |
Why?
|
Health Resources | 8 | 2019 | 948 | 0.600 |
Why?
|
Hepatitis B | 4 | 2024 | 710 | 0.570 |
Why?
|
Nigeria | 9 | 2023 | 781 | 0.560 |
Why?
|
Cohort Studies | 52 | 2022 | 41718 | 0.550 |
Why?
|
Clinical Laboratory Techniques | 6 | 2020 | 746 | 0.530 |
Why?
|
Antiviral Agents | 10 | 2024 | 3070 | 0.530 |
Why?
|
United States | 76 | 2024 | 72971 | 0.530 |
Why?
|
Pneumonia, Pneumocystis | 6 | 2002 | 242 | 0.520 |
Why?
|
Budgets | 5 | 2020 | 232 | 0.510 |
Why?
|
Housing | 1 | 2020 | 683 | 0.510 |
Why?
|
Smoking Cessation | 6 | 2024 | 2085 | 0.500 |
Why?
|
Continuity of Patient Care | 10 | 2022 | 1078 | 0.500 |
Why?
|
Point-of-Care Systems | 8 | 2019 | 1217 | 0.500 |
Why?
|
Urban Health Services | 1 | 2016 | 177 | 0.490 |
Why?
|
Drug Substitution | 1 | 2018 | 292 | 0.490 |
Why?
|
Universities | 1 | 2020 | 1004 | 0.490 |
Why?
|
Adenine | 8 | 2020 | 995 | 0.490 |
Why?
|
Hepatitis C | 5 | 2019 | 1594 | 0.490 |
Why?
|
Models, Statistical | 13 | 2020 | 5098 | 0.480 |
Why?
|
Hepatitis B, Chronic | 3 | 2024 | 413 | 0.460 |
Why?
|
Hepatitis C, Chronic | 5 | 2015 | 1032 | 0.450 |
Why?
|
Antifungal Agents | 4 | 2017 | 760 | 0.450 |
Why?
|
Lamivudine | 3 | 2024 | 367 | 0.450 |
Why?
|
Anti-Infective Agents | 7 | 2009 | 986 | 0.440 |
Why?
|
Patient Acceptance of Health Care | 10 | 2016 | 3232 | 0.430 |
Why?
|
Middle Aged | 89 | 2024 | 223233 | 0.430 |
Why?
|
Lost to Follow-Up | 5 | 2020 | 124 | 0.430 |
Why?
|
Viremia | 1 | 2016 | 726 | 0.420 |
Why?
|
Health Services Accessibility | 9 | 2017 | 5519 | 0.410 |
Why?
|
Emigrants and Immigrants | 2 | 2016 | 550 | 0.410 |
Why?
|
Glucuronosyltransferase | 1 | 2012 | 136 | 0.400 |
Why?
|
Abnormalities, Drug-Induced | 2 | 2012 | 337 | 0.390 |
Why?
|
Office Visits | 1 | 2016 | 595 | 0.390 |
Why?
|
Oxazines | 4 | 2024 | 358 | 0.390 |
Why?
|
Dideoxynucleosides | 3 | 2024 | 135 | 0.380 |
Why?
|
Primary Health Care | 9 | 2017 | 4746 | 0.380 |
Why?
|
Prevalence | 25 | 2022 | 15851 | 0.380 |
Why?
|
Behavior Therapy | 2 | 2015 | 886 | 0.370 |
Why?
|
Antibodies, Heterophile | 2 | 2001 | 128 | 0.370 |
Why?
|
Delivery of Health Care | 7 | 2021 | 5363 | 0.370 |
Why?
|
Dementia | 2 | 2024 | 2741 | 0.370 |
Why?
|
Infectious Mononucleosis | 2 | 2001 | 133 | 0.360 |
Why?
|
HIV Protease Inhibitors | 4 | 2007 | 430 | 0.360 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2019 | 951 | 0.360 |
Why?
|
Sensitivity and Specificity | 30 | 2021 | 14672 | 0.350 |
Why?
|
Drugs, Generic | 5 | 2024 | 457 | 0.350 |
Why?
|
Alkynes | 6 | 2024 | 326 | 0.350 |
Why?
|
Resource Allocation | 3 | 2009 | 354 | 0.350 |
Why?
|
Decision Support Techniques | 12 | 2020 | 2006 | 0.340 |
Why?
|
Genotype | 11 | 2020 | 13035 | 0.340 |
Why?
|
Cyclopropanes | 6 | 2024 | 436 | 0.330 |
Why?
|
Risk-Taking | 5 | 2013 | 1023 | 0.330 |
Why?
|
World Health Organization | 8 | 2014 | 1327 | 0.330 |
Why?
|
Mycobacterium avium-intracellulare Infection | 3 | 1999 | 82 | 0.330 |
Why?
|
Young Adult | 41 | 2024 | 59980 | 0.330 |
Why?
|
Bacteriological Techniques | 1 | 2010 | 277 | 0.320 |
Why?
|
Microbial Sensitivity Tests | 5 | 2015 | 1969 | 0.320 |
Why?
|
Ganciclovir | 2 | 2001 | 256 | 0.320 |
Why?
|
Substance Abuse, Intravenous | 4 | 2023 | 530 | 0.310 |
Why?
|
Public Health | 6 | 2024 | 2681 | 0.310 |
Why?
|
Zimbabwe | 5 | 2022 | 135 | 0.310 |
Why?
|
Pyridones | 4 | 2024 | 819 | 0.310 |
Why?
|
Treatment Failure | 9 | 2017 | 2658 | 0.290 |
Why?
|
Delayed Diagnosis | 1 | 2011 | 454 | 0.290 |
Why?
|
Ribavirin | 5 | 2015 | 395 | 0.290 |
Why?
|
State Health Plans | 3 | 2009 | 220 | 0.290 |
Why?
|
Survival Analysis | 17 | 2019 | 10092 | 0.290 |
Why?
|
HIV Seropositivity | 4 | 2013 | 963 | 0.280 |
Why?
|
Drug Administration Schedule | 9 | 2020 | 4855 | 0.280 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2014 | 2038 | 0.280 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1444 | 0.280 |
Why?
|
Sputum | 8 | 2021 | 514 | 0.280 |
Why?
|
Group Homes | 2 | 2024 | 59 | 0.280 |
Why?
|
Quality Indicators, Health Care | 2 | 2017 | 1804 | 0.280 |
Why?
|
Mycoses | 6 | 2007 | 386 | 0.270 |
Why?
|
Lipopolysaccharides | 4 | 2021 | 2217 | 0.270 |
Why?
|
Hospitalization | 5 | 2024 | 10815 | 0.270 |
Why?
|
Africa South of the Sahara | 6 | 2021 | 751 | 0.270 |
Why?
|
Guidelines as Topic | 7 | 2017 | 1396 | 0.270 |
Why?
|
Incidence | 18 | 2024 | 21526 | 0.270 |
Why?
|
Monte Carlo Method | 7 | 2024 | 1250 | 0.270 |
Why?
|
Mycobacterium tuberculosis | 4 | 2019 | 1911 | 0.270 |
Why?
|
Tuberculosis, Pulmonary | 3 | 2019 | 836 | 0.270 |
Why?
|
Adolescent | 45 | 2024 | 89046 | 0.270 |
Why?
|
Early Diagnosis | 9 | 2021 | 1188 | 0.270 |
Why?
|
Cost of Illness | 8 | 2007 | 1951 | 0.260 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3234 | 0.260 |
Why?
|
Pentamidine | 3 | 2002 | 44 | 0.260 |
Why?
|
Drug Therapy, Combination | 11 | 2012 | 6310 | 0.260 |
Why?
|
Secondary Prevention | 1 | 2012 | 1472 | 0.260 |
Why?
|
Treatment Outcome | 36 | 2020 | 65295 | 0.250 |
Why?
|
Motivation | 1 | 2015 | 2021 | 0.250 |
Why?
|
Community Health Services | 3 | 2018 | 659 | 0.250 |
Why?
|
Brazil | 4 | 2024 | 1250 | 0.250 |
Why?
|
Cytomegalovirus Infections | 4 | 2002 | 836 | 0.240 |
Why?
|
Medical Assistance | 2 | 2002 | 108 | 0.240 |
Why?
|
Diagnostic Tests, Routine | 5 | 2021 | 788 | 0.240 |
Why?
|
AIDS Vaccines | 2 | 2016 | 900 | 0.240 |
Why?
|
Quinolizines | 1 | 2024 | 20 | 0.240 |
Why?
|
Markov Chains | 11 | 2015 | 976 | 0.240 |
Why?
|
Azocines | 1 | 2024 | 20 | 0.240 |
Why?
|
Immunotherapy, Active | 1 | 2004 | 58 | 0.230 |
Why?
|
Time Factors | 22 | 2018 | 40154 | 0.230 |
Why?
|
Ritonavir | 4 | 2015 | 331 | 0.220 |
Why?
|
Public Sector | 3 | 2019 | 266 | 0.220 |
Why?
|
Dapsone | 2 | 2002 | 55 | 0.220 |
Why?
|
Public Health Administration | 1 | 2006 | 242 | 0.220 |
Why?
|
Piperazines | 4 | 2024 | 2548 | 0.220 |
Why?
|
Decision Support Systems, Clinical | 1 | 2012 | 1178 | 0.210 |
Why?
|
Alkaloids | 1 | 2024 | 192 | 0.210 |
Why?
|
Clinical Trials as Topic | 10 | 2023 | 8048 | 0.210 |
Why?
|
Quality of Life | 18 | 2024 | 13485 | 0.210 |
Why?
|
Antibodies, Monoclonal | 1 | 2020 | 9245 | 0.210 |
Why?
|
Kenya | 3 | 2022 | 757 | 0.210 |
Why?
|
Forecasting | 5 | 2024 | 2936 | 0.200 |
Why?
|
Voluntary Programs | 4 | 2011 | 48 | 0.200 |
Why?
|
Program Evaluation | 6 | 2015 | 2505 | 0.200 |
Why?
|
Financing, Government | 1 | 2006 | 473 | 0.200 |
Why?
|
Risk Factors | 31 | 2024 | 74886 | 0.200 |
Why?
|
Boston | 11 | 2010 | 9360 | 0.200 |
Why?
|
Practice Guidelines as Topic | 7 | 2012 | 7435 | 0.200 |
Why?
|
Naphthoquinones | 1 | 2002 | 60 | 0.200 |
Why?
|
Patient Dropouts | 2 | 2020 | 411 | 0.200 |
Why?
|
CD4-Positive T-Lymphocytes | 6 | 2013 | 4405 | 0.200 |
Why?
|
Depression | 3 | 2023 | 8234 | 0.200 |
Why?
|
Genetic Testing | 2 | 2012 | 3591 | 0.190 |
Why?
|
Quarantine | 1 | 2024 | 186 | 0.190 |
Why?
|
Massachusetts | 10 | 2024 | 8890 | 0.190 |
Why?
|
France | 6 | 2012 | 496 | 0.190 |
Why?
|
Antiprotozoal Agents | 1 | 2002 | 93 | 0.190 |
Why?
|
Reverse Transcriptase Inhibitors | 6 | 2020 | 620 | 0.190 |
Why?
|
Infant | 18 | 2023 | 36485 | 0.190 |
Why?
|
Alcohol-Related Disorders | 1 | 2004 | 243 | 0.190 |
Why?
|
Patient Simulation | 2 | 2020 | 300 | 0.180 |
Why?
|
Preventive Health Services | 1 | 2006 | 570 | 0.180 |
Why?
|
Thyroiditis | 1 | 2001 | 86 | 0.180 |
Why?
|
Europe | 3 | 2023 | 3432 | 0.180 |
Why?
|
Community Health Centers | 3 | 2021 | 469 | 0.180 |
Why?
|
Pregnancy | 20 | 2024 | 30238 | 0.180 |
Why?
|
Models, Econometric | 4 | 2007 | 215 | 0.170 |
Why?
|
Outpatient Clinics, Hospital | 4 | 2007 | 392 | 0.170 |
Why?
|
Antibodies, Viral | 3 | 2020 | 3212 | 0.170 |
Why?
|
Breast Feeding | 4 | 2018 | 1362 | 0.170 |
Why?
|
Iodide Peroxidase | 1 | 2001 | 295 | 0.170 |
Why?
|
Condoms | 2 | 2024 | 337 | 0.170 |
Why?
|
Disease Progression | 15 | 2015 | 13646 | 0.160 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2002 | 348 | 0.160 |
Why?
|
Alcoholism | 3 | 2005 | 1980 | 0.160 |
Why?
|
Direct Service Costs | 3 | 2006 | 61 | 0.160 |
Why?
|
Fees and Charges | 1 | 2020 | 189 | 0.160 |
Why?
|
Sarcoma, Kaposi | 1 | 2022 | 376 | 0.160 |
Why?
|
Interferons | 2 | 2014 | 716 | 0.160 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2019 | 4054 | 0.160 |
Why?
|
Regression Analysis | 7 | 2016 | 6331 | 0.160 |
Why?
|
Cause of Death | 3 | 2017 | 3717 | 0.160 |
Why?
|
Herpesvirus 4, Human | 2 | 2001 | 1079 | 0.160 |
Why?
|
Botswana | 1 | 2022 | 1056 | 0.160 |
Why?
|
Protease Inhibitors | 2 | 2012 | 750 | 0.150 |
Why?
|
Infant, Newborn | 13 | 2024 | 26396 | 0.150 |
Why?
|
HLA-B Antigens | 2 | 2010 | 330 | 0.150 |
Why?
|
Masks | 1 | 2020 | 212 | 0.150 |
Why?
|
Infant Care | 1 | 2019 | 182 | 0.150 |
Why?
|
Travel | 1 | 2024 | 805 | 0.150 |
Why?
|
Serologic Tests | 1 | 2020 | 382 | 0.150 |
Why?
|
Colposcopy | 1 | 1999 | 151 | 0.150 |
Why?
|
National Health Programs | 2 | 2019 | 443 | 0.150 |
Why?
|
Asymptomatic Infections | 1 | 2019 | 136 | 0.150 |
Why?
|
Thyrotropin | 1 | 2001 | 834 | 0.150 |
Why?
|
Drug Combinations | 3 | 2024 | 2086 | 0.140 |
Why?
|
Smoking | 4 | 2020 | 9081 | 0.140 |
Why?
|
Outpatients | 5 | 2018 | 1600 | 0.140 |
Why?
|
Zidovudine | 4 | 2015 | 625 | 0.140 |
Why?
|
Nystatin | 1 | 2017 | 22 | 0.140 |
Why?
|
Postnatal Care | 1 | 2019 | 273 | 0.140 |
Why?
|
HIV Seroprevalence | 2 | 2011 | 89 | 0.140 |
Why?
|
Gentian Violet | 1 | 2017 | 25 | 0.140 |
Why?
|
Fluconazole | 1 | 1997 | 153 | 0.140 |
Why?
|
Candidiasis, Oral | 1 | 2017 | 57 | 0.140 |
Why?
|
Public Health Practice | 1 | 2019 | 220 | 0.140 |
Why?
|
Urban Population | 5 | 2017 | 2044 | 0.130 |
Why?
|
Cultural Competency | 1 | 2019 | 303 | 0.130 |
Why?
|
Child | 21 | 2024 | 80771 | 0.130 |
Why?
|
Medically Uninsured | 1 | 2001 | 838 | 0.130 |
Why?
|
Demography | 4 | 2015 | 1641 | 0.130 |
Why?
|
Observation | 1 | 2017 | 310 | 0.130 |
Why?
|
Vaginal Smears | 1 | 1999 | 505 | 0.130 |
Why?
|
United States Food and Drug Administration | 1 | 2024 | 1672 | 0.130 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.130 |
Why?
|
HIV Fusion Inhibitors | 2 | 2006 | 82 | 0.130 |
Why?
|
Patents as Topic | 1 | 2016 | 111 | 0.120 |
Why?
|
Cryptococcus | 1 | 2015 | 28 | 0.120 |
Why?
|
Research Personnel | 1 | 2020 | 589 | 0.120 |
Why?
|
Developmental Disabilities | 1 | 2024 | 1518 | 0.120 |
Why?
|
Malnutrition | 2 | 2014 | 632 | 0.120 |
Why?
|
Counseling | 5 | 2013 | 1553 | 0.120 |
Why?
|
Pneumocystis | 1 | 1995 | 55 | 0.120 |
Why?
|
Antigens, Fungal | 1 | 2015 | 69 | 0.120 |
Why?
|
Hepatitis B virus | 3 | 2024 | 531 | 0.120 |
Why?
|
Statistics, Nonparametric | 2 | 2016 | 2850 | 0.120 |
Why?
|
Melanoma | 2 | 2007 | 5702 | 0.120 |
Why?
|
Circumcision, Male | 1 | 2016 | 148 | 0.120 |
Why?
|
Government Programs | 2 | 2007 | 278 | 0.120 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 67 | 0.120 |
Why?
|
Epidemics | 1 | 2020 | 516 | 0.120 |
Why?
|
Africa | 2 | 2014 | 725 | 0.120 |
Why?
|
Inpatients | 2 | 2006 | 2563 | 0.120 |
Why?
|
Poverty | 1 | 2006 | 2719 | 0.120 |
Why?
|
Cryptococcosis | 1 | 2015 | 99 | 0.120 |
Why?
|
Delayed-Action Preparations | 2 | 2015 | 965 | 0.120 |
Why?
|
Pregnancy Complications, Infectious | 6 | 2021 | 2183 | 0.120 |
Why?
|
Retrospective Studies | 16 | 2021 | 81659 | 0.110 |
Why?
|
Health Education | 1 | 2001 | 1058 | 0.110 |
Why?
|
Rural Population | 4 | 2018 | 2321 | 0.110 |
Why?
|
Sexual Behavior | 7 | 2024 | 2196 | 0.110 |
Why?
|
Liver Function Tests | 2 | 2012 | 526 | 0.110 |
Why?
|
Prenatal Diagnosis | 1 | 2001 | 1271 | 0.110 |
Why?
|
Mycobacterium Infections | 2 | 2006 | 122 | 0.110 |
Why?
|
Alcohol Drinking | 3 | 2004 | 4045 | 0.110 |
Why?
|
Skin Neoplasms | 2 | 2007 | 5859 | 0.110 |
Why?
|
HIV Envelope Protein gp41 | 2 | 2006 | 306 | 0.110 |
Why?
|
Tuberculosis, Multidrug-Resistant | 2 | 2012 | 941 | 0.110 |
Why?
|
Pyrrolidinones | 1 | 2014 | 116 | 0.110 |
Why?
|
Epidemiologic Research Design | 1 | 2017 | 368 | 0.110 |
Why?
|
Patients | 1 | 2020 | 908 | 0.110 |
Why?
|
Child, Preschool | 9 | 2022 | 42606 | 0.110 |
Why?
|
Gross Domestic Product | 1 | 2013 | 77 | 0.110 |
Why?
|
Stavudine | 2 | 2010 | 85 | 0.110 |
Why?
|
Antibodies | 1 | 2001 | 2419 | 0.110 |
Why?
|
Geographic Information Systems | 1 | 2015 | 283 | 0.110 |
Why?
|
Medically Underserved Area | 1 | 2015 | 268 | 0.110 |
Why?
|
Risk Assessment | 8 | 2022 | 24299 | 0.110 |
Why?
|
Decision Making | 5 | 2020 | 3951 | 0.100 |
Why?
|
Infant Mortality | 1 | 2018 | 752 | 0.100 |
Why?
|
Hepatitis B e Antigens | 2 | 2024 | 135 | 0.100 |
Why?
|
Interprofessional Relations | 1 | 2019 | 1000 | 0.100 |
Why?
|
HIV Antibodies | 4 | 2023 | 1340 | 0.100 |
Why?
|
Prospective Studies | 16 | 2023 | 54886 | 0.100 |
Why?
|
Physician's Role | 1 | 1999 | 923 | 0.100 |
Why?
|
HIV Reverse Transcriptase | 3 | 2009 | 214 | 0.100 |
Why?
|
Health Policy | 5 | 2024 | 2698 | 0.100 |
Why?
|
Antigen Presentation | 2 | 2010 | 1250 | 0.100 |
Why?
|
Decision Trees | 5 | 2009 | 508 | 0.100 |
Why?
|
Interferon-alpha | 4 | 2015 | 909 | 0.100 |
Why?
|
Hepacivirus | 2 | 2017 | 1342 | 0.100 |
Why?
|
Liver Cirrhosis | 3 | 2024 | 1959 | 0.100 |
Why?
|
Aged | 19 | 2024 | 171319 | 0.100 |
Why?
|
Self Care | 1 | 2017 | 800 | 0.100 |
Why?
|
Patient Transfer | 1 | 2019 | 788 | 0.100 |
Why?
|
Patient Participation | 1 | 2001 | 1444 | 0.100 |
Why?
|
Cardiovascular Diseases | 2 | 2017 | 15645 | 0.100 |
Why?
|
Hepatitis C Antibodies | 1 | 2012 | 151 | 0.100 |
Why?
|
Drug Resistance, Bacterial | 1 | 2019 | 1063 | 0.100 |
Why?
|
Geography | 2 | 2013 | 651 | 0.100 |
Why?
|
Pandemics | 5 | 2024 | 8736 | 0.090 |
Why?
|
Bacterial Infections | 4 | 2007 | 1390 | 0.090 |
Why?
|
Specialization | 1 | 2016 | 778 | 0.090 |
Why?
|
Treatment Refusal | 2 | 2006 | 433 | 0.090 |
Why?
|
Vaccination | 2 | 2022 | 3434 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2330 | 0.090 |
Why?
|
State Government | 2 | 2006 | 388 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1434 | 0.090 |
Why?
|
Cross-Sectional Studies | 8 | 2022 | 26325 | 0.090 |
Why?
|
Tuberculin Test | 1 | 2011 | 205 | 0.090 |
Why?
|
Microscopy | 2 | 2019 | 903 | 0.090 |
Why?
|
Skin Diseases | 1 | 1999 | 1083 | 0.090 |
Why?
|
Pyrimidinones | 2 | 2011 | 385 | 0.090 |
Why?
|
Recurrence | 4 | 2020 | 8504 | 0.090 |
Why?
|
Teratogens | 1 | 2011 | 119 | 0.090 |
Why?
|
Mental Health Services | 1 | 2022 | 1733 | 0.090 |
Why?
|
Candidiasis | 2 | 2008 | 366 | 0.090 |
Why?
|
Genes, MHC Class I | 1 | 2010 | 236 | 0.090 |
Why?
|
Quality Improvement | 2 | 2017 | 3854 | 0.080 |
Why?
|
Pharmacogenetics | 2 | 2011 | 682 | 0.080 |
Why?
|
Aged, 80 and over | 8 | 2024 | 59548 | 0.080 |
Why?
|
Reminder Systems | 1 | 2012 | 389 | 0.080 |
Why?
|
Public Assistance | 1 | 2009 | 47 | 0.080 |
Why?
|
False Positive Reactions | 3 | 2020 | 959 | 0.080 |
Why?
|
Patient Selection | 1 | 2001 | 4256 | 0.080 |
Why?
|
Systems Integration | 1 | 2011 | 425 | 0.080 |
Why?
|
Multivariate Analysis | 7 | 2018 | 12069 | 0.080 |
Why?
|
Follow-Up Studies | 12 | 2019 | 39317 | 0.080 |
Why?
|
Survival Rate | 3 | 2012 | 12823 | 0.080 |
Why?
|
Age Distribution | 2 | 2023 | 2870 | 0.080 |
Why?
|
Appointments and Schedules | 1 | 2012 | 443 | 0.080 |
Why?
|
Primary Prevention | 1 | 2016 | 1188 | 0.080 |
Why?
|
Latent Tuberculosis | 1 | 2011 | 223 | 0.080 |
Why?
|
Immunoassay | 1 | 2012 | 744 | 0.080 |
Why?
|
Polymerase Chain Reaction | 3 | 2010 | 6067 | 0.080 |
Why?
|
Sentinel Surveillance | 2 | 2007 | 292 | 0.080 |
Why?
|
Data Collection | 3 | 2011 | 3321 | 0.080 |
Why?
|
Oligopeptides | 1 | 2014 | 1195 | 0.080 |
Why?
|
HIV Antigens | 2 | 2010 | 328 | 0.080 |
Why?
|
Logistic Models | 5 | 2018 | 13284 | 0.080 |
Why?
|
Methotrexate | 1 | 1995 | 1718 | 0.070 |
Why?
|
Diagnostic Services | 1 | 2007 | 33 | 0.070 |
Why?
|
Value of Life | 2 | 2001 | 98 | 0.070 |
Why?
|
Health Services Research | 1 | 2015 | 1815 | 0.070 |
Why?
|
Self Report | 2 | 2017 | 3773 | 0.070 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4357 | 0.070 |
Why?
|
Health Expenditures | 1 | 2020 | 2390 | 0.070 |
Why?
|
Aging | 2 | 2024 | 8729 | 0.070 |
Why?
|
Hemoglobins, Abnormal | 1 | 2008 | 119 | 0.070 |
Why?
|
DNA, Viral | 3 | 2024 | 2201 | 0.070 |
Why?
|
Disabled Persons | 2 | 2024 | 1209 | 0.070 |
Why?
|
Meningitis, Cryptococcal | 1 | 2008 | 65 | 0.070 |
Why?
|
Health Care Rationing | 3 | 2017 | 435 | 0.070 |
Why?
|
Medical Informatics | 1 | 2014 | 744 | 0.070 |
Why?
|
Lung Neoplasms | 2 | 2024 | 13491 | 0.070 |
Why?
|
Toxoplasmosis, Cerebral | 1 | 2006 | 19 | 0.070 |
Why?
|
Mozambique | 2 | 2017 | 55 | 0.070 |
Why?
|
Staining and Labeling | 1 | 2010 | 1076 | 0.070 |
Why?
|
Telemedicine | 1 | 2024 | 3110 | 0.070 |
Why?
|
Public Policy | 1 | 2010 | 551 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2014 | 1596 | 0.060 |
Why?
|
Anus Neoplasms | 2 | 2000 | 336 | 0.060 |
Why?
|
Hospitals, Municipal | 2 | 1995 | 19 | 0.060 |
Why?
|
DNA, Bacterial | 1 | 2010 | 1477 | 0.060 |
Why?
|
Internationality | 1 | 2011 | 1006 | 0.060 |
Why?
|
Dideoxyadenosine | 1 | 2024 | 9 | 0.060 |
Why?
|
Proportional Hazards Models | 5 | 2024 | 12536 | 0.060 |
Why?
|
Self Disclosure | 1 | 2006 | 248 | 0.060 |
Why?
|
Tennessee | 1 | 2024 | 123 | 0.060 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2006 | 212 | 0.060 |
Why?
|
Drug Utilization | 1 | 2011 | 1190 | 0.060 |
Why?
|
Disclosure | 2 | 2023 | 755 | 0.060 |
Why?
|
Drug Therapy | 2 | 2020 | 504 | 0.060 |
Why?
|
Calibration | 2 | 2020 | 817 | 0.060 |
Why?
|
Referral and Consultation | 3 | 2012 | 3618 | 0.060 |
Why?
|
Health Behavior | 2 | 2012 | 2650 | 0.060 |
Why?
|
Private Sector | 1 | 2007 | 397 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1982 | 0.060 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2006 | 216 | 0.060 |
Why?
|
Antitubercular Agents | 3 | 2020 | 1380 | 0.060 |
Why?
|
Federal Government | 1 | 2006 | 266 | 0.060 |
Why?
|
Needlestick Injuries | 1 | 2004 | 71 | 0.060 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 2188 | 0.060 |
Why?
|
Rifampin | 2 | 2019 | 350 | 0.060 |
Why?
|
HLA Antigens | 1 | 2009 | 1334 | 0.060 |
Why?
|
Longitudinal Studies | 3 | 2010 | 14766 | 0.060 |
Why?
|
Drug Discovery | 1 | 2012 | 1068 | 0.060 |
Why?
|
Medical Records Systems, Computerized | 1 | 2010 | 1196 | 0.060 |
Why?
|
Gene Products, gag | 1 | 2004 | 318 | 0.050 |
Why?
|
Internal Medicine | 1 | 2011 | 1064 | 0.050 |
Why?
|
Mental Disorders | 1 | 2023 | 6873 | 0.050 |
Why?
|
Odds Ratio | 4 | 2013 | 9660 | 0.050 |
Why?
|
Ambulatory Care | 4 | 2011 | 2780 | 0.050 |
Why?
|
Predictive Value of Tests | 5 | 2011 | 15424 | 0.050 |
Why?
|
Peptide Fragments | 2 | 2006 | 5141 | 0.050 |
Why?
|
Heterosexuality | 2 | 2016 | 309 | 0.050 |
Why?
|
Pneumonia | 1 | 1995 | 2159 | 0.050 |
Why?
|
Prisoners | 1 | 2006 | 315 | 0.050 |
Why?
|
Biopsy | 1 | 1995 | 6777 | 0.050 |
Why?
|
Toxoplasmosis | 2 | 2007 | 94 | 0.050 |
Why?
|
Prognosis | 3 | 2019 | 29963 | 0.050 |
Why?
|
Ukraine | 1 | 2023 | 151 | 0.050 |
Why?
|
Chickenpox | 1 | 2003 | 95 | 0.050 |
Why?
|
Registries | 2 | 2016 | 8351 | 0.050 |
Why?
|
Parasitic Diseases | 1 | 2003 | 76 | 0.050 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2024 | 294 | 0.050 |
Why?
|
Siblings | 1 | 2007 | 828 | 0.050 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3837 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3112 | 0.050 |
Why?
|
Stroke | 1 | 2024 | 9746 | 0.050 |
Why?
|
Ethambutol | 2 | 2012 | 59 | 0.050 |
Why?
|
Atovaquone | 1 | 2002 | 56 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6513 | 0.050 |
Why?
|
HIV Long-Term Survivors | 3 | 2010 | 140 | 0.050 |
Why?
|
Polyethylene Glycols | 1 | 2008 | 1188 | 0.050 |
Why?
|
Statistics as Topic | 1 | 2008 | 2350 | 0.050 |
Why?
|
Risk | 4 | 2015 | 9606 | 0.050 |
Why?
|
Hospitals | 2 | 2017 | 3883 | 0.050 |
Why?
|
Social Stigma | 2 | 2023 | 788 | 0.050 |
Why?
|
Lead Poisoning | 2 | 1995 | 323 | 0.050 |
Why?
|
Health Services | 1 | 2006 | 755 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2006 | 1733 | 0.050 |
Why?
|
Bleomycin | 1 | 2022 | 492 | 0.050 |
Why?
|
Age Factors | 2 | 2016 | 18401 | 0.050 |
Why?
|
Bisexuality | 2 | 2000 | 295 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4593 | 0.050 |
Why?
|
Biomedical Research | 1 | 2016 | 3464 | 0.050 |
Why?
|
Sex Distribution | 1 | 2006 | 2276 | 0.050 |
Why?
|
Pharmaceutical Services | 1 | 2002 | 145 | 0.050 |
Why?
|
Etoposide | 1 | 2022 | 639 | 0.040 |
Why?
|
Financial Management | 1 | 2002 | 161 | 0.040 |
Why?
|
Morbidity | 3 | 2012 | 1754 | 0.040 |
Why?
|
Data Interpretation, Statistical | 2 | 2017 | 2698 | 0.040 |
Why?
|
Algorithms | 4 | 2014 | 14098 | 0.040 |
Why?
|
Insurance Coverage | 2 | 2002 | 1945 | 0.040 |
Why?
|
Isoniazid | 2 | 2012 | 279 | 0.040 |
Why?
|
Reproducibility of Results | 7 | 2014 | 20169 | 0.040 |
Why?
|
Florida | 1 | 2001 | 417 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2012 | 3488 | 0.040 |
Why?
|
Anonymous Testing | 1 | 1999 | 10 | 0.040 |
Why?
|
Health Status Indicators | 2 | 2003 | 969 | 0.040 |
Why?
|
Mortality | 3 | 2019 | 2909 | 0.040 |
Why?
|
Vincristine | 1 | 2022 | 1040 | 0.040 |
Why?
|
Leukoplakia, Hairy | 1 | 1999 | 10 | 0.040 |
Why?
|
Cost Savings | 3 | 2015 | 904 | 0.040 |
Why?
|
Amino Acid Substitution | 1 | 2004 | 1743 | 0.040 |
Why?
|
Malaria | 2 | 2007 | 1246 | 0.040 |
Why?
|
History, 21st Century | 1 | 2006 | 1574 | 0.040 |
Why?
|
Medicaid | 2 | 2005 | 2836 | 0.040 |
Why?
|
Folliculitis | 1 | 1999 | 25 | 0.040 |
Why?
|
Arthritis, Rheumatoid | 1 | 1995 | 3778 | 0.040 |
Why?
|
HIV Seronegativity | 1 | 2000 | 209 | 0.040 |
Why?
|
Dermatomycoses | 1 | 1999 | 45 | 0.040 |
Why?
|
Substance-Related Disorders | 2 | 2015 | 4422 | 0.040 |
Why?
|
Liver | 1 | 1995 | 7578 | 0.040 |
Why?
|
Drugs, Investigational | 1 | 2001 | 211 | 0.040 |
Why?
|
New York | 1 | 2001 | 879 | 0.040 |
Why?
|
Organizational Innovation | 1 | 2002 | 539 | 0.040 |
Why?
|
Rifabutin | 1 | 1999 | 53 | 0.040 |
Why?
|
Haiti | 2 | 2014 | 553 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2020 | 404 | 0.040 |
Why?
|
Los Angeles | 1 | 2019 | 245 | 0.040 |
Why?
|
Clarithromycin | 1 | 1999 | 87 | 0.040 |
Why?
|
Organizations | 1 | 2019 | 172 | 0.040 |
Why?
|
Tumor Virus Infections | 1 | 2001 | 437 | 0.040 |
Why?
|
Eligibility Determination | 1 | 2002 | 421 | 0.040 |
Why?
|
Drug Resistance, Microbial | 1 | 2001 | 831 | 0.040 |
Why?
|
Ethics | 1 | 1998 | 93 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2008 | 2783 | 0.040 |
Why?
|
History, 20th Century | 1 | 2006 | 2765 | 0.040 |
Why?
|
Canada | 1 | 2023 | 2127 | 0.040 |
Why?
|
Administration, Oral | 2 | 2017 | 4026 | 0.040 |
Why?
|
Alanine | 1 | 2020 | 613 | 0.040 |
Why?
|
Malawi | 1 | 2019 | 312 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2012 | 12793 | 0.040 |
Why?
|
Efficiency, Organizational | 1 | 2002 | 697 | 0.040 |
Why?
|
Leukocyte Count | 2 | 1992 | 1606 | 0.040 |
Why?
|
Azithromycin | 1 | 1999 | 201 | 0.040 |
Why?
|
Intention | 1 | 2020 | 347 | 0.040 |
Why?
|
Hospitals, Teaching | 1 | 2002 | 1156 | 0.040 |
Why?
|
Developed Countries | 2 | 2012 | 453 | 0.040 |
Why?
|
Chi-Square Distribution | 2 | 2001 | 3431 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2004 | 1801 | 0.030 |
Why?
|
Probability | 2 | 2005 | 2476 | 0.030 |
Why?
|
Viral Proteins | 1 | 2004 | 1801 | 0.030 |
Why?
|
Neural Tube Defects | 1 | 2019 | 255 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2014 | 4881 | 0.030 |
Why?
|
Pediatrics | 1 | 2012 | 3621 | 0.030 |
Why?
|
Systems Analysis | 1 | 2017 | 168 | 0.030 |
Why?
|
Immunization | 1 | 2021 | 1218 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2001 | 751 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2001 | 1527 | 0.030 |
Why?
|
Deoxycytidine | 2 | 2013 | 886 | 0.030 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2019 | 335 | 0.030 |
Why?
|
Occupational Diseases | 1 | 2004 | 1456 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2001 | 4049 | 0.030 |
Why?
|
Nutrition Surveys | 1 | 2023 | 1738 | 0.030 |
Why?
|
Nursing Homes | 1 | 2023 | 1084 | 0.030 |
Why?
|
Child, Orphaned | 1 | 2016 | 55 | 0.030 |
Why?
|
Dermatology | 1 | 2006 | 905 | 0.030 |
Why?
|
Evolution, Molecular | 1 | 2004 | 1893 | 0.030 |
Why?
|
Diet | 1 | 2014 | 8089 | 0.030 |
Why?
|
Protozoan Infections | 1 | 1995 | 38 | 0.030 |
Why?
|
Costs and Cost Analysis | 2 | 2011 | 1666 | 0.030 |
Why?
|
Population Surveillance | 1 | 2006 | 2594 | 0.030 |
Why?
|
Sex Factors | 1 | 2009 | 10622 | 0.030 |
Why?
|
Chronic Disease | 2 | 2011 | 9362 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 1999 | 450 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2001 | 1139 | 0.030 |
Why?
|
Urban Health | 2 | 2008 | 533 | 0.030 |
Why?
|
Nicotine | 1 | 2020 | 680 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1728 | 0.030 |
Why?
|
Administration, Topical | 1 | 2017 | 703 | 0.030 |
Why?
|
Internship and Residency | 2 | 2011 | 5947 | 0.030 |
Why?
|
Clinical Protocols | 2 | 2009 | 1443 | 0.030 |
Why?
|
Chelation Therapy | 1 | 1995 | 77 | 0.030 |
Why?
|
Opiate Substitution Treatment | 1 | 2019 | 452 | 0.030 |
Why?
|
Africa, Eastern | 1 | 2014 | 76 | 0.030 |
Why?
|
Postpartum Period | 1 | 2001 | 1198 | 0.030 |
Why?
|
Fees, Medical | 1 | 1994 | 111 | 0.030 |
Why?
|
Edetic Acid | 1 | 1995 | 277 | 0.030 |
Why?
|
Homosexuality | 2 | 2009 | 269 | 0.030 |
Why?
|
Portugal | 1 | 2013 | 91 | 0.030 |
Why?
|
Blood Proteins | 1 | 1979 | 1190 | 0.030 |
Why?
|
Truth Disclosure | 1 | 1998 | 434 | 0.030 |
Why?
|
Electrolytes | 1 | 1994 | 279 | 0.030 |
Why?
|
Prenatal Care | 1 | 2001 | 1158 | 0.030 |
Why?
|
Cholesterol | 1 | 2002 | 2905 | 0.030 |
Why?
|
Health Status | 2 | 2003 | 4091 | 0.030 |
Why?
|
Pain Measurement | 1 | 2003 | 3584 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2017 | 1587 | 0.030 |
Why?
|
Streptomycin | 1 | 2012 | 69 | 0.030 |
Why?
|
Focus Groups | 1 | 2019 | 1460 | 0.030 |
Why?
|
Kanamycin | 1 | 2012 | 63 | 0.030 |
Why?
|
Therapy, Computer-Assisted | 1 | 1995 | 265 | 0.030 |
Why?
|
Perception | 1 | 2019 | 1205 | 0.030 |
Why?
|
Blood Specimen Collection | 1 | 1994 | 238 | 0.030 |
Why?
|
Pilot Projects | 2 | 2005 | 8732 | 0.030 |
Why?
|
Precancerous Conditions | 1 | 1999 | 980 | 0.020 |
Why?
|
Recombinant Proteins | 3 | 2008 | 6507 | 0.020 |
Why?
|
Models, Organizational | 1 | 1995 | 548 | 0.020 |
Why?
|
Urinalysis | 1 | 2014 | 369 | 0.020 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2011 | 63 | 0.020 |
Why?
|
Patient Preference | 1 | 2019 | 947 | 0.020 |
Why?
|
Confidence Intervals | 2 | 2010 | 2920 | 0.020 |
Why?
|
Infection Control | 1 | 2019 | 984 | 0.020 |
Why?
|
Exercise Test | 1 | 1999 | 2188 | 0.020 |
Why?
|
Analysis of Variance | 3 | 2013 | 6215 | 0.020 |
Why?
|
Research Design | 2 | 2020 | 6210 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 4572 | 0.020 |
Why?
|
Insurance, Health, Reimbursement | 1 | 1994 | 388 | 0.020 |
Why?
|
Causality | 1 | 2017 | 1253 | 0.020 |
Why?
|
Hospitals, Rural | 1 | 2012 | 174 | 0.020 |
Why?
|
Blood Gas Analysis | 1 | 1992 | 383 | 0.020 |
Why?
|
Hospitals, Urban | 1 | 2012 | 495 | 0.020 |
Why?
|
Sickness Impact Profile | 1 | 2012 | 299 | 0.020 |
Why?
|
Reference Standards | 1 | 2014 | 1011 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 1994 | 602 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 2010 | 7871 | 0.020 |
Why?
|
District of Columbia | 1 | 2010 | 159 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 3804 | 0.020 |
Why?
|
Social Support | 2 | 2017 | 2192 | 0.020 |
Why?
|
Family Characteristics | 1 | 2015 | 1002 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 146 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 223 | 0.020 |
Why?
|
Vulnerable Populations | 1 | 2015 | 718 | 0.020 |
Why?
|
Drug Administration Routes | 1 | 2010 | 152 | 0.020 |
Why?
|
CD4-CD8 Ratio | 1 | 2009 | 114 | 0.020 |
Why?
|
False Negative Reactions | 1 | 2011 | 570 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2428 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2011 | 238 | 0.020 |
Why?
|
Family | 1 | 2020 | 3210 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2001 | 4560 | 0.020 |
Why?
|
Papillomavirus Infections | 1 | 2001 | 1639 | 0.020 |
Why?
|
Sexual Partners | 1 | 2014 | 805 | 0.020 |
Why?
|
Selection, Genetic | 2 | 2004 | 877 | 0.020 |
Why?
|
Virus Diseases | 1 | 1995 | 722 | 0.020 |
Why?
|
Clinical Trials, Phase IV as Topic | 1 | 2009 | 30 | 0.020 |
Why?
|
Data Mining | 1 | 2014 | 561 | 0.020 |
Why?
|
Drug Tolerance | 1 | 1991 | 365 | 0.020 |
Why?
|
Hospitals, University | 1 | 2011 | 570 | 0.020 |
Why?
|
Contact Tracing | 1 | 2011 | 274 | 0.020 |
Why?
|
Alleles | 2 | 2010 | 6893 | 0.020 |
Why?
|
Consent Forms | 1 | 2009 | 55 | 0.020 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7848 | 0.020 |
Why?
|
Cell Count | 1 | 2013 | 1825 | 0.020 |
Why?
|
Bottle Feeding | 1 | 2008 | 67 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2017 | 10393 | 0.020 |
Why?
|
Medical Record Linkage | 1 | 2010 | 286 | 0.020 |
Why?
|
Models, Immunological | 1 | 2010 | 516 | 0.020 |
Why?
|
Aerosols | 1 | 1991 | 634 | 0.020 |
Why?
|
Cough | 1 | 1992 | 598 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 1994 | 1320 | 0.020 |
Why?
|
Qualitative Research | 1 | 2019 | 3139 | 0.020 |
Why?
|
Lead | 1 | 1994 | 882 | 0.020 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2012 | 592 | 0.020 |
Why?
|
Jamaica | 1 | 2007 | 54 | 0.020 |
Why?
|
Fractures, Bone | 1 | 2020 | 2062 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2011 | 1697 | 0.020 |
Why?
|
Triage | 1 | 1994 | 995 | 0.020 |
Why?
|
Pregnancy Complications | 1 | 2001 | 2971 | 0.020 |
Why?
|
Caribbean Region | 1 | 2007 | 193 | 0.020 |
Why?
|
Kidney Failure, Chronic | 1 | 2020 | 2495 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2001 | 3449 | 0.020 |
Why?
|
Echocardiography | 1 | 1999 | 5042 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2010 | 4648 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2014 | 2353 | 0.020 |
Why?
|
Antipsychotic Agents | 1 | 1979 | 3078 | 0.020 |
Why?
|
Health Promotion | 1 | 2017 | 2210 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2007 | 507 | 0.020 |
Why?
|
Linear Models | 3 | 2003 | 5875 | 0.010 |
Why?
|
Interviews as Topic | 2 | 2003 | 2741 | 0.010 |
Why?
|
Language | 1 | 2014 | 1550 | 0.010 |
Why?
|
HLA-A3 Antigen | 1 | 2004 | 34 | 0.010 |
Why?
|
Virology | 1 | 2005 | 76 | 0.010 |
Why?
|
Georgia | 1 | 2005 | 186 | 0.010 |
Why?
|
Caregivers | 1 | 2017 | 2302 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2009 | 878 | 0.010 |
Why?
|
Amino Acids | 1 | 2010 | 1712 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2722 | 0.010 |
Why?
|
Survivors | 1 | 1995 | 2381 | 0.010 |
Why?
|
Health Personnel | 2 | 2011 | 3387 | 0.010 |
Why?
|
Dyspnea | 1 | 1992 | 1352 | 0.010 |
Why?
|
Temperance | 1 | 2004 | 88 | 0.010 |
Why?
|
Review Literature as Topic | 1 | 2006 | 297 | 0.010 |
Why?
|
Sequence Analysis, RNA | 1 | 2012 | 2040 | 0.010 |
Why?
|
Chickenpox Vaccine | 1 | 2003 | 39 | 0.010 |
Why?
|
HIV Protease | 1 | 2003 | 99 | 0.010 |
Why?
|
Investments | 1 | 2005 | 148 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2013 | 2337 | 0.010 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 1 | 2004 | 213 | 0.010 |
Why?
|
Immunodominant Epitopes | 1 | 2004 | 244 | 0.010 |
Why?
|
Blotting, Western | 1 | 2011 | 5022 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2011 | 3154 | 0.010 |
Why?
|
Protein Conformation | 1 | 2010 | 3948 | 0.010 |
Why?
|
Body Constitution | 1 | 2002 | 273 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2012 | 5891 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 2004 | 17608 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2006 | 1364 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 1994 | 3928 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2004 | 827 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5388 | 0.010 |
Why?
|
Acute Disease | 1 | 2011 | 7236 | 0.010 |
Why?
|
Mesoridazine | 1 | 1979 | 2 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2011 | 2972 | 0.010 |
Why?
|
Drug Hypersensitivity | 1 | 2008 | 903 | 0.010 |
Why?
|
Hydroxylation | 1 | 1979 | 139 | 0.010 |
Why?
|
Chlorpromazine | 1 | 1979 | 111 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2010 | 3076 | 0.010 |
Why?
|
Point Mutation | 1 | 2003 | 1591 | 0.010 |
Why?
|
Social Class | 1 | 2007 | 2007 | 0.010 |
Why?
|
Self Efficacy | 1 | 2002 | 643 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2007 | 15925 | 0.010 |
Why?
|
Medicare | 1 | 1994 | 6813 | 0.010 |
Why?
|
Body Mass Index | 1 | 2014 | 13048 | 0.010 |
Why?
|
Infection Control Practitioners | 1 | 1995 | 12 | 0.010 |
Why?
|
Phylogeny | 1 | 2003 | 2840 | 0.010 |
Why?
|
United States Public Health Service | 1 | 1995 | 31 | 0.010 |
Why?
|
Myocardial Revascularization | 1 | 1999 | 795 | 0.010 |
Why?
|
Drug Interactions | 1 | 2000 | 1419 | 0.010 |
Why?
|
Dyslexia, Acquired | 1 | 1995 | 14 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5886 | 0.010 |
Why?
|
Penicillamine | 1 | 1995 | 60 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2006 | 5311 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 1994 | 285 | 0.010 |
Why?
|
Hypertension | 1 | 2013 | 8615 | 0.010 |
Why?
|
Body Composition | 1 | 2002 | 2454 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2004 | 13411 | 0.010 |
Why?
|
Base Sequence | 1 | 2003 | 12414 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2003 | 4780 | 0.010 |
Why?
|
Education | 1 | 1995 | 531 | 0.010 |
Why?
|
Length of Stay | 1 | 2005 | 6489 | 0.010 |
Why?
|
Disease Outbreaks | 1 | 2001 | 1761 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 12790 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 16036 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2002 | 3324 | 0.010 |
Why?
|
Protein Binding | 1 | 1979 | 9327 | 0.000 |
Why?
|
Life Style | 1 | 1998 | 3931 | 0.000 |
Why?
|
Mutation | 1 | 2009 | 30211 | 0.000 |
Why?
|
Societies, Medical | 1 | 1995 | 3964 | 0.000 |
Why?
|
Clinical Competence | 1 | 1994 | 4859 | 0.000 |
Why?
|
Myocardial Infarction | 1 | 1999 | 11513 | 0.000 |
Why?
|
Animals | 1 | 2004 | 168965 | 0.000 |
Why?
|